Last reviewed · How we verify
EVL arm
EVL (endoscopic variceal ligation) is a mechanical intervention that uses elastic bands to ligate esophageal varices and prevent bleeding.
EVL (endoscopic variceal ligation) is a mechanical intervention that uses elastic bands to ligate esophageal varices and prevent bleeding. Used for Prevention and treatment of esophageal variceal bleeding in patients with portal hypertension.
At a glance
| Generic name | EVL arm |
|---|---|
| Also known as | Everolimus |
| Sponsor | Hospital Vall d'Hebron |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
EVL is an endoscopic procedure in which elastic bands are deployed around bleeding or at-risk esophageal varices to occlude blood flow and prevent variceal hemorrhage. The bands cause tissue necrosis and fibrosis, leading to variceal obliteration. This is a procedural intervention rather than a pharmacological drug.
Approved indications
- Prevention and treatment of esophageal variceal bleeding in patients with portal hypertension
Common side effects
- Chest discomfort or pain
- Dysphagia
- Ulceration at ligation site
- Rebleeding
Key clinical trials
- Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC (PHASE2)
- Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response (PHASE4)
- The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation (PHASE3)
- 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients (PHASE4)
- Prevention of Esophageal Variceal Rebleeding (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVL arm CI brief — competitive landscape report
- EVL arm updates RSS · CI watch RSS
- Hospital Vall d'Hebron portfolio CI